Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Navicare Biotech Co., Ltd. (8472) Financial Statements

Navicare Biotech Co., Ltd. Financial Overview

Navicare Biotech Co., Ltd.'s market cap is currently NT$853.98M. The company's EPS TTM is NT$-0.64; its P/E ratio is -70.14; and it has a dividend yield of 3.42%. Navicare Biotech Co., Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24Dec 23Mar 23Dec 21
Income Statement
Total RevenueNT$ 478.07MNT$ 337.03MNT$ 388.50MNT$ 331.55MNT$ 305.28M
Gross ProfitNT$ 172.16MNT$ 211.87MNT$ 281.82MNT$ 280.10MNT$ 283.92M
Operating IncomeNT$ -31.82MNT$ -76.78MNT$ -90.16MNT$ -53.45MNT$ 12.12M
EBITDANT$ -15.09MNT$ -54.05MNT$ -46.75MNT$ -81.95MNT$ 22.46M
Net IncomeNT$ -23.27MNT$ -78.46MNT$ -51.83MNT$ -82.68MNT$ 10.77M
Balance Sheet
Cash & Short-Term InvestmentsNT$ 230.31MNT$ 99.12MNT$ 141.01MNT$ 242.88MNT$ 658.58M
Total AssetsNT$ 1.05BNT$ 999.54MNT$ 1.18BNT$ 1.21BNT$ 1.05B
Total DebtNT$ 327.47MNT$ 260.97MNT$ 248.84MNT$ 232.22MNT$ 13.26M
Net DebtNT$ 168.28MNT$ 181.98MNT$ 162.53MNT$ 116.80MNT$ -123.06M
Total LiabilitiesNT$ 779.12MNT$ 714.47MNT$ 818.89MNT$ 796.38MNT$ 521.48M
Stockholders' EquityNT$ 270.50MNT$ 285.07MNT$ 363.53MNT$ 415.36MNT$ 527.27M
Cash Flow
Free Cash FlowNT$ -4.12MNT$ -72.22MNT$ -145.37MNT$ -474.62MNT$ -74.47M
Operating Cash FlowNT$ -3.17MNT$ -63.49MNT$ -108.19MNT$ -68.41MNT$ -68.70M
Investing Cash FlowNT$ 8.65MNT$ 49.10MNT$ 68.92MNT$ -157.56MNT$ 70.60M
Financing Cash FlowNT$ 74.59MNT$ 7.07MNT$ 10.17MNT$ 205.06MNT$ -49.52M

Currency in TWD

Navicare Biotech Co., Ltd. Earnings and Revenue History

-300M0300M600M-30 %-15 %0 %15 %EarningsProfit Margin2019202020212022202320242025RevenueEarningsProfit Margin
Income Statement >

Navicare Biotech Co., Ltd. Liabilities to Assets

0500M1B1.5B48 %60 %72 %84 %LiabilitiesLiabilities to Assets2019202020212022202320242025AssetsLiabilitiesLiabilities to Assets
Balance Sheet >

Navicare Biotech Co., Ltd. Cash Flow

-200M-100M0100M200M300M2019202020212022202320242025OperatingInvestingFinancing
Cash Flow >

Navicare Biotech Co., Ltd. Forecast EPS vs Actual EPS

-0.6-0.4-0.200.20.4Q3 25Q4 25Q1 26Q2 26Q3 26EPS EstimateBeatMiss
Earnings >